Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Mol Cancer Ther. 2018 Mar 28;17(5):921–930. doi: 10.1158/1535-7163.MCT-17-0302

Figure 4. PARP-1 knockdown inhibits IL-8 expression in both HER2+ parental and trastuzumab resistant breast cancer cells.

Figure 4

Quantitative real-time RT-PCR analysis was performed with total RNAs isolated from (A) BT-474 trastuzumab resistant, (B) UACC-812 trastuzumab resistant, and (C) BT-474 parent cells that were transfected with 20 nM of control (CON) or PARP-1 siRNA for 48 hours, serum-starved for 18 hours, and then stimulated with 10 ng/ml of tumor necrosis factor-α (TNF-α) for 2 hours. (D) BT-474 TR were serum starved and treated for four hours with DMSO or 10 μM ABT-888 and then treated with TNF-α for an additional 2 hours. One μg of isolated RNA was reverse transcribed to cDNA and then analyzed by qRT-PCR for IL-8 and GAPDH expression. The figures are representative images from one of three independent experiments performed in triplicate. A one-way ANOVA test was performed followed by a t-test to calculate the significance between groups. *p<0.05 and ***p<0.001